ABSTRACT The clinical effects of intravenous streptokinase in patients with acute myocardial infarction were compared with those of intracoronary streptokinase in a randomized, prospective study. Comparisons were also made with a historical control group. Fifty patients were entered into the study at 2.4 + 1.2 hr after onset of pain, and 27 were assigned to intravenous and 23 to intracoronary therapy. The doses of streptokinase averaged 212,000 U ic and 845,000 U iv (0.75 x 106 U/5 hr, n = 14 or 106 U/1 hr, n = 13). Results of studies of the two intravenous dosage schedules were similar and so were combined. Streptokinase was administered at 2.8 + 1.0 hr after onset of pain in the intravenous and at 4.3 + 1.4 hr in the intracoronary drug group (p < .001). Convalescent (day 10) radionuclide ejection fractions were 54 + 14% for the intravenous and 50 + 16% for the intracoronary drug group. Change in ejection fraction from day 1 to 10 tended to be greater after intravenous drug: 5.1% (p < .08) vs 1.2% (NS). Semiquantitative regional wall motion indexes in the infarct zone showed significant and similar modest improvement from admission to day 10 in both groups (p < .02). Accelerated enzyme-release kinetics were noted after both therapies. Times of peak enzyme levels for patients on intravenous and intracoronary drug were, respectively, 12.5 ± 5.0 and 11.5 + 4.3 hr for creatine kinase MB isoenzyme and 31.7 + 11.8 and 28.1 + 12.7 hr for lactic dehydrogenase (LDH). Peak LDH-1 level was lower in patients receiving intravenous drug than in the historical control group (p < .05). Electrocardiographically summed ST segments diminished rapidly after therapy in both groups; Q wave development was similar and overall R wave loss was equivalent and less extensive compared with in historical control subjects. Infarct pain requiring morphine was diminished similarly in both treatment groups. Incidence of early arrhythmias and heart failure also did not differ. Posttherapy ischemic events and early surgery tended to be more common in the intracoronary group and bleeding was more common in the intravenous group. Intravenous drug did not decrease early hospital mortality (intravenous drug -5, historical control = 4, intracoronary drug -1); the differences in this parameter among groups were not significant. At convalescent angiographic evaluation, anterograde perfusion was present in 73% of those receiving intravenous and 76% of those receiving intracoronary drug. Thus, favorable relative effects were noted on cardiac function, clinical evaluations, and hospital course after intravenous streptokinase in early survivors of myocardial infarction and use of intravenous drug has the advantage of earlier and easier application. Additional studies will be required to address effects on mortality.
streptokinase.8' 12 These results are leading to more widespread application of thrombolytic therapy.'4 However, a minority of hospitals have coronary angiographic laboratories, and even these are not all prepared to provide 24 hr coverage. Moreover, it is unlikely that intracoronary administration of streptokinase at an average of less than 3 to 4 hr after onset of symptoms will be feasible.
These considerations have stimulated interest in the use of short-term, relatively high-dose intravenous streptokinase.'5 Large-scale studies of effects of standard doses of intravenous streptokinase on patients with acute myocardial infarction have been performed in the past decade.'6' 1" While the relative safety of these infusions was established, the study designs were flawed and the results mixed.'8 Intravenous streptokinase has not to date been approved for general use in this application. The feasibility of coronary thrombolysis by high-dose, short-term infusion of streptokinase was recently confirmed by Schroder et al. ' 5 However, as with intracoronary streptokinase, randomized studies are needed to adequately assess safety and potential benefit with respect to hospital course.
We recently demonstrated that early application of intracoronary streptokinase may be associated with a beneficial overall effect on in-hospital course of patients with acute myocardial infarction. 13 In an effort to allow earlier, easier application of thrombolytic therapy, we next undertook a prospective, randomized study to compare the intravenous with the intracoronary drug in treatment of patients with acute myocardial infarction. Results were also compared with those in our comparable historical control group of patients that did not receive thrombolytic therapy.
Methods
Recruitment of patients. Patients with ischemic chest pain of less than 4 hr duration and with electrocardiographic ST segment elevation of at least 2 mm (0.2 mV) that was unresponsive to nitroglycerin were candidates for inclusion in the study. ' 3 Exclusion criteria included hemodynamic (shock) or rhythm instability precluding possible immediate catheterization and specific contraindications to thrombolytic therapy. '8 After consent was obtained from physician and patient, a letter was opened that contained each patient's random treatment assignment to catheterization with infusion of intracoronary streptokinase, administered at coronary angiography, or to intravenous streptokinase administered in the coronary care unit. Approximately 80% of hospitalized patients qualifying for the study could be recruited. Six patients initially randomly assigned to therapy (two to intravenous and four to intracoronary drug) were excluded within the first 24 hr because they subsequently refused to undergo catheterization (two patients) or because there was inadequate historical or electrocardiographic evidence on entry of acute transmural myocardial infarction, as determined on investigator review (four patients). (One of the excluded patients initially assigned to the intracoronary drug group and presenting with heart failure later died. Her initial ST elevation was due to a ventricular aneurysm from an old infarction.) No patient who qualified for study died between entry and the beginning of thrombolytic therapy, and all patients who qualified and received therapy were followed until death or hospital discharge. Standard medical therapy provided to both groups included prophylactic lidocaine for the first 24 hr of hospitalization, morphine sulfate as required for pain, and oxygen and nitroglycerin as indicated.
Patients assigned to treatment with intracoronary streptokinase were catheterized shortly after admission to the hospital by the Judkins (femoroarterial) approach and heparin (5000 units) was given to each after arterial entry. Aortic and left ventricular pressures were measured and left ventriculography and selective coronary angiography were performed in which the presumably uninvolved vessel was visualized first. After occlusion (total or subtotal) of the vessel supplying the infarct zone had been confirmed, streptokinase (1000 U/ml dextrose or saline) was administered through the selective coronary arterial catheter. An initial bolus of 10,000 to 20,000 U streptokinase was given, followed by an infusion of 5,000 U/min (range 3000 to 6000). A soft angiographic guidewire was used to probe obstructions not reopening by 45 to 60 min. After reperfusion was established, the infusion rate was decreased to 3500 U/min (range 2000 to 5000) for an additional 30 to 45 min. Coronary angiography was repeated at intervals of 10 to 15 min during administration of streptokinase. Subtotal occlusion was treated with an infusion of 100,000 U. The left ventriculographic examination was repeated at the end of the study.
Patients assigned to intravenous streptokinase therapy received the drug according to one of two regimens. The initial group of patients (n = 14) was given 750,000 according to a standard protocol consisting of a 250,000 U loading dose (over 10 to 15 min) and then 100,000 U/hr for 5 hr. After the safety of intravenous dosing had been established, a high-dose, shorter term infusion was used in another group of 13 patients. This consisted of a 500,000 U loading dose (over 10 to 15 min) and 10,000 U/min for 50 min (total 1,000,000 U over 1 hr). There were no significant differences between the slow-and fast-rate infusion groups with respect to patient characteristics, enzyme kinetics, ejection fraction, or clinical evidence of reperfusion; the groups were thus combined for comparison with the group receiving intracoronary drug.
After streptokinase (intracoronary or intravenous), a heparin infusion was initiated (800 to 1000 U/hr) when the partial thromboplastin time fell to 80 to 100 sec; the dose was titrated to maintain thromboplastin time in this range for 3 days. Antiplatelet drugs (aspirin, 300 mg twice daily and dipyridamole, 75 mg twice daily) or warfarin were then given for the rest of the hospital stay and during the first 3 outpatient months. Decisions regarding other medical therapy, cardiac surgery, and coronary balloon angioplasty were not specified by the DDeter.mined on admission in samples from nonfasting patients.
EClinical coronary artery disease in first-degree relative at -60 years of age.
smoking habits, family history, obesity, blood pressure and heart rate, and levels of serum glucose and cholesterol. Diuretics or /3-blockers were used by a similar minority of patients in each group. Patients assigned to intravenous therapy were randomized at a slightly earlier time (2.1 vs 2.8 hr, p < .05). Incidences of coronary anatomic disease and initial ventricular function were also shown to be comparable in the groups (see below).
Results of blinded observation
Comparative changes in ejection fraction. Early (day 1) and late (day 10) posttreatment left ventricular ejection fractions, assessed by radionuclide ventriculography, are illustrated in figure 1 for surviving patients (two refused restudy). Ejection fractions on day 1 the intracoronary streptokinase (current study) and historical control groups did not achieve significance.
Regional wall motion (table 2) . Echocardiographic regional wall motion indexes for global and infarct segments were similar in both treatment groups on admission, day 1, and before discharge (day 10). Changes (improvement) in global wall motion index from admission to discharge, determined with paired data, were minor and not significant (average of two observers). (Changes in index after 1 day transiently favored the intracoronary group [p < .01]). In contrast, significant improvement became evident when restricting analysis to the infarct zone: an improvement of 0.3 of an index unit occurred in both intravenous and intracoronary drug groups between admission and day 10 (both p < .02).
Myocardial enzyme kinetics (table 3;figures 2 and 3). Similar accelerated enzyme-release kinetics were associated with both intravenous and intracoronary therapies, and kinetics in each group differed significantly from those in historical control subjects. Times to peak en- coronary drug groups, with early loss, then stabilization; R wave amplitudes at the time of discharge from the hospital were greater after thrombolytic therapy than after the treatment that the control group received (p < .002, figure 5 ). Clinically apparent bleeding (upper gastrointestinal source) was noted in four patients after intravenous and one patient after intracoronary steptokinase. Source of bleeding was a gastric (in a patient receiving intracoronary drug), pyloric, and duodenal ulcer in one patient each, was associated with the nasogastric tube in one, and was unidentified in one (coffee grounds emesis). All were successfully treated with fluid or blood-component replacement. Aminocaproic acid was used in two. Bleeding occurred within 6 hr of streptokinase infusion in three patients (all receiving intravenous drug) and during subsequent heparin therapy in two. Anemia ascribed to other causes was also noted in three patients receiving intravenous and two receiving intracoronary drug. One patient developed an urticarial rash 1 day after intravenous therapy.
Mortality in our elderly population requires discussion. In the historical control group, four hospital deaths occurred (15% mortality rate) and among the 50 patients undergoing thrombolytic therapy in this study, 612 six deaths occurred (12% mortality). This mortality was age related: 3.6% (1/22) in patients age 65 years old or younger; 23% (5/22) in those over 65. Five patients in the intravenous drug group died, a rate similar to that among the historical control patients. One patient in the intracoronary drug group died. The trend toward fewer deaths in the intracoronary vs intravenous drug group was not statistically significant, however. All deaths were associated with pump failure, with or without terminal arrhythmia. Deaths in the intravenous drug group occurred at 1, 4, and 8 hr and 2 and 3 days and could not be specifically ascribed to thrombolytic therapy. Postmortem examinations were performed in three patients in the intravenous drug group and demonstrated rupture of the ventricular septum in one (this patient died after 8 hr, with intracoronary clot still occluding the anterior descending), free wall rupture in another (dying after 2 days), and extensive infarction in the third (dying after 3 days). Progressive shock and arrhythmia were noted in the patient receiving intravenous drug who died at 1 hr. Cardiogenic shock and limited gastrointestinal bleed-ing (blood volume maintained) characterized the course in the patient receiving intravenous drug who died at 4 hr. The single death in the intracoronary drug group, in a patient initially near shock and successfully reperfused, occurred 1 hr after thrombolysis and may have been the result of reocclusion (postmortem declined).
Angiographic and therapeutic observations (table 5). In the intracoronary drug group acute coronary angiography documented total occlusion in 21 (91%) and subtotal occlusion in two patients. Reperfusion was established in 87% (20/23) of patients overall and 86% (18/21) of those with totally occluded vessels. (Initial reperfusion was accomplished by contrast injection in one and guidewire manipulation in two.) Intracoronary streptokinase was administered 4.3 ± 1.4 hr after onset of symptoms, representing an average delay of 1.4 hr after admission. Total streptokinase dose averaged 210,000 U. Occluded vessels were reperfused after an average of 23 min (range 0 to 60); total infusion time averaged 56 ± 20 min. In therapeutically reperfused patients with paired, interpretable angiograms, ejection fraction increased immediately after therapy from 53.9 ± 5.2% to 61.5 ± 11.2% (p < .07, n = 11).
The intravenous drug group was characterized by a substantially shorter delay occurring between entry and drug administration (0.7 ± 0.3 hr), leading to delivery of drug an average of 2.8 ± 1.0 hr after onset of pain (p < .001, intravenous vs intracoronary drug). Using a combination of indirect clinical indexes27 (change in pain or rhythm, early enzyme peak, rapid ST segment resolution) we estimated that 59% (n = 16) of the patients in the intravenous drug group reperfused early (< 1 hr), 26% (n = 7) reperfused with some delay (1 to 4 hr), and 15% (n = 4) failed to reperfuse. Relatively early peaking of levels of CK-MB isoenzyme (at <14 hr after entry) occurred in a similar high percentage of patients receiving intrave- drug. No significant differences in characteristics or major end points were observed between the low-(n -14) and high-rate (n = 13) infusion groups. Mean ages were 63 ± 12 and 58 + 13 years, respectively. Time of entry into the study averaged 2.1 and 2. 1 hr. Anterior infarction occurred in 43% and 38%. Increases in radionuclide ejection fraction averaged 5.2 and 6.4 percentage points. Times to peak level of CK-MB were 13.7 and 10.0 hr and to peak level of LDH-l, 31.7 and 30.6 hr. Electrocardiographic predischarge Q waves averaged 3.7 vs 3.4 and relative R wave amplitudes, 44% and 44%. Bleeding problems occurred in two in each group. A similar number were believed to have both early (n = 8, 8) and intermediate reperfusion (n -4, 3), and similar late patency rates (75%, 70%) were observed. Deaths by group numbered one (low rate) and four (high rate) (p = NS).
Discussion
The present study compared the effects on hospital course of intravenous and intracoronary streptokinase in patients presenting with acute myocardial infarction. Results after intravenous streptokinase were also compared with those after standard therapy in a comparable historical control group not treated with thrombolytic therapy.'3 Overall, our study suggests that intravenous and intracoronary streptokinase have approximately equivalent overall effects on hospital course and clinical and laboratory variables used to evaluate patients with myocardial infarction surviving the first 8 hr. In a comparison with a historical control group not treated with the drug, several variables indicated a significant benefit of streptokinase therapy. Our study does not provide evidence for a reduction in early mortality after intravenous streptokinase compared with therapy that the historical control patients 614 received, but this analysis was limited by the small study population. The use of intracoronary streptokinase has several disadvantages that might limit its widespread and effective application. A small minority of hospital centers have cardiac catheterization facilities able to provide 24 hr coverage. Even in these, inevitable delays prolong the time to application of streptokinase, jeopardizing the potential beneficial effects of reperfusion. 11-1 Intravenous streptokinase, if proved effective, could be applied readily and rapidly in virtually every medical care facility. 28 Recently, Schroder et al.`5 demonstrated the feasibility of thrombolysis with short-term intravenous infusions of streptokinase. In 11 of 21 patients (52%) studied angiographically, occluded coronary arteries were opened within 1 hr after starting the infusion. In 84% of a larger group (93 patients), eventual patency of the infarct-related coronary artery was demonstrated by angiography in the fourth week. Early peaking serum CK-MB curves suggested that recanalization may have occurred in most patients within 1 to 2 hr of application. Myocardial salvage was suggested by improvement in local contraction disorders in the recanalized group and by a significant relationship between infarct size and time from onset of symptoms to treatment, with benefit being particularly evident in patients treated within 3 hr of symptom onset. Streptokinase doses were 500,000 or 1,500,000 U and clinically evident bleeding was not problematic. Intravenous streptokinase had previously been applied to patients with myocardial infarction in several large trials undertaken during the 1970s. Generally, these trials were flawed by errors in study design,'8 but some of the larger trials suggested a potential beneficial effect on mortality.'6 17 In these trials, the level of safety of standard doses of streptokinase appeared acceptable. Our study documented the ability to apply thrombolytic therapy substantially earlier by the intravenous route in patients with acute myocardial infarction, with a relatively favorable effect on ventricular function. Intravenous streptokinase was applied by 2.8 hr (vs 4.3 hr for intracoronary drug). The 5.1 percentage point average increase in ejection fraction during convalescence, as determined by radionuclide ventriculography, was significant in comparison with the average decrease in function ( -3.0%) noted in the historical control group. Improved global function after streptokinase was also observed by Schroder et al. '5 The small improvement in ejection fraction after intracoronary streptokinase did not achieve significance in the present study. This result is consistent with randomized trials from Michigan" and Washington'2 and is slightly inferior to that noted in our previous trial.'3 (Intracoronary drug was applied slightly later in the present study and a somewhat greater incidence of posttherapy ischemic events occurred.) Echocardiographic regional wall motion in the infarct zone showed similar overall improvement in both groups. Compensatory changes in opposite wall motion may explain the insignificant global index change, as observed by others. 7 29 The kinetics of myocardial enzyme release were similar in the two treatment groups and differed from that in the control group. Early peaking of levels of myocardial enzymes appears to be a consistent finding after coronary thrombolysis3' 3 15, 30, 31 and was also noted in the present study. Clinical and animal studies32 suggest that rapid release of CK-MB, whether therapeutically or spontaneously achieved,33 is a marker of early reperfusion. Rapid enzyme release has also been associated with differential improvement in left ventricular function in treated9' 30 and untreated9' 3 patient groups. The similar times to enzyme peaks in our intravenous and intracoronary drug groups provide evidence for a similar average time to reperfusion. Results of animal and human studies suggest an increase in the total amount of CK released into the serum after reperfusion.3' 3>32 The result is greater total enzyme release (by up to two to three times) for equivalent infarct volumes. Thus, the finding of roughly equivalent peak and time-integrated CK enzyme values for the two streptokinase-treated groups and the historical control group in our study is consistent with myocardial salvage. The lower peak levels of LDH and LDH-1 in the intravenous drug vs the control group are also suggestive of salvage. However, the mechanisms of myocardial LDH release during myocardial infarction and reperfusion require further experimental study, especially since nonmyocytic components (including white cells and red cells) participating in the exudative and hemorrhagic responses to ischemic injury may be a substantial source of LDH.
Electrocardiographic evolutionary changes were favorable after intravenous streptokinase and this is consistent with previous observations.4 13 recently developed based on R wave loss and Q wave development and have been correlated with left ventricular function after myocardial infarction.35' 36 The observed electrocardiographic results in our study may thus be interpreted as supporting a modest reduction in infarct size. The reason for initially rapid electrocardiographic evolution on reperfusion is unclear. The possibility of reperfusion injury has recently been considered and is leading to experimental attempts to limit its extent.37 -9 The hospital course in surviving patients was favorable in those receiving intravenous streptokinase. A marked decrease in pain (assessed by the need for morphine) has been observed after reperfusion"' " and was similarly noted after intravenous and intracoronary therapy in this study. Average change in Killip heart failure class was comparable in both treatment groups. Incidence of acute arrhythmias did not differ significantly between treatment groups, and late ventricular arrhythmias were actually less frequent in patients in the intravenous drug group. The occurrence of postinfarct ischemic events favored the intravenous group, although the reason for this is unclear. Bleeding episodes tended to be more common in the intravenous drug group, but were successfully managed. The greater frequency of interventions (surgery, balloon dilatation) in the intracoronary drug group could be related to more frequent pain recurrence and the fact that there was anatomic information available as a result of early angiography. Because interventions were often performed before the final convalescent evaluations, they must be considered, together with acute streptokinase, as part of the overall therapeutic intervention. However, any presumed beneficial effects of surgical intervention would, if anything, bias the study against the intravenous streptokinase group since more interventions were performed in the intracoronary drug group.
Our study is too small to assess significant differences in mortality, but overall and age-related rates were generally similar to average rates reported in other studies.27'40 Mortality after intravenous streptokinase was similar to that in historical control patients (five vs four deaths). The lower mortality after intracoronary drug ( 16 ' 17 Further controlled studies will thus be required to assess the safety of and questions about mortality after high-dose, short-term intravenous streptokinase.
Certain limitations of our study should be recognized. Catheterization data were not obtained in the intravenous drug group on admission to the hospital since our protocol was designed to mimic the clinical situation. Also, early coronary angiography in the intravenous drug group was sacrificed in favor of earlier institution of therapy, with the potential for greater clinical benefit. Our control study group was a historical rather than a concurrent one. However, these patients showed excellent matching, were similarly recruited and evaluated, and received otherwise similar therapy.13 Other studies have documented the acute kinetics of coronary thrombolysis after intravenous streptokinase1528 3 a 50% to 60% reperfusion rate in the first hour has been consistently observed.
Evidence for early reperfusion in our study included similarities in clinical course, enzyme kinetics, and electrocardiographic evolution in the intravenous and intracoronary steptokinase groups. 15 28 Despite the favorable comparisons between the streptokinase-treated and untreated (historical control) groups, the gains suggested are generally modest. Approaches that allow even earlier and more efficient intervention5' and the application of adjunctive therapies that assist in salvaging greater amounts of myocardium are indicated.52
In summary, the clinical effects of intravenous and intracoronary streptokinase in patients with acute myocardial infarction were compared in a randomized, prospective fashion. Indirect evidence suggested a roughly similar rate of early reperfusion. Similar or superior effects on left ventricular function, incidence of arrhythmias, and postinfarction ischemic complications were noted in survivors in the intravenous drug group. Although early mortality in this group tended to be higher, this could not be ascribed to drug. These results should stimulate additional studies of intravenous streptokinase in patients with acute myocardial infarction to further assess questions of safety and efficacy.
